Clinical trial NCT00795912 - References

Heart Failure — A Study Of The Usage Of Statins In A Community Heart Failure Population

Citation(s)

•   Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, González-Arencibia C
  C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002 Jun;4(3):331-6.
•   Braunstein JB, Cheng A, Cohn G, Aggarwal M, Nass CM, Blumenthal RS
  Lipid disorders: justification of methods and goals of treatment. Chest. 2001 Sep;120(3):979-88. Review.
•   Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang XF, Frangogiannis NG
  Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation. 2007 Nov 6;116(19):2127-38. Epub 2007 Oct 22.
•   Clearfield MB
  Statins: balancing benefits, efficacy and safety. Expert Opin Pharmacother. 2002 May;3(5):469-77. Review.
•   Cleland JG, Swedberg K, Poole-Wilson PA
  Successes and failures of current treatment of heart failure. Lancet. 1998 Aug;352 Suppl 1:SI19-28. Review.
•   Gullestad L, Kjekshus J, Damås JK, Ueland T, Yndestad A, Aukrust P
  Agents targeting inflammation in heart failure. Expert Opin Investig Drugs. 2005 May;14(5):557-66. Review.
•   Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA
  B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004 Mar 5;94(4):453-61. Epub 2004 Jan 15.
•   Kjekshus J
  Debate: Statins should be used in patients with heart failure. Curr Control Trials Cardiovasc Med. 2001;2(6):268-270.
•   Kronmal RA, Cain KC, Ye Z, Omenn GS
  Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med. 1993 May 10;153(9):1065-73.
•   Krum H, McMurray JJ
  Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 2002 May 15;39(10):1567-73.
•   Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K
  Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007 Feb 20;115(7):888-95. Epub 2007 Feb 5.
•   Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, Díez J
  Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004 Sep 7;110(10):1263-8. Epub 2004 Aug 16.
•   Rauchhaus M, Coats AJ, Anker SD
  The endotoxin-lipoprotein hypothesis. Lancet. 2000 Sep 9;356(9233):930-3. Review.
•   Riesen WF, Engler H, Risch M, Korte W, Noseda G
  Short-term effects of atorvastatin on C-reactive protein. Eur Heart J. 2002 May;23(10):794-9.
•   Swynghedauw B
  Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999 Jan;79(1):215-62. Review.
•   Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M; GISSI-HF Investigators
  Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004 Aug;6(5):635-41.
•   Weber KT, Sun Y, Tyagi SC, Cleutjens JP
  Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 1994 Mar;26(3):279-92. Review.
•   Zannad F, Alla F, Dousset B, Perez A, Pitt B
  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000 Nov 28;102(22):2700-6. Erratum in: Circulation 2001 Jan 23;103(3):476.

A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis

Details for clinical trial NCT00795912